WASHINGTON, DC 20549

                                   FORM 12b-25

                           NOTIFICATION OF LATE FILING

                                                 Commission File Number 0-28498

(Check one)

|_| Form 10-K and Form 10-KSB   |_| Form 11-K

|_| Form 20-F  |X| Form 10-Q and Form 10-QSB  |_| Form N-SAR

For period ended: June 30, 2007

|_| Transition Report on Form 10-K and Form 10-KSB

|_| Transition Report on Form 20-F

|_| Transition Report on Form 11-K

|_| Transition Report on Form 10-Q and Form 10-QSB

|_| Transition Report on Form N-SAR

For the transition period ended _____________________________________________

Read Attached Instruction Sheet Before Preparing Form.  Please Print or Type.

     Nothing in this form shall be  construed to imply that the  Commission  has
verified any information contained herein.

     If the  notification  relates  to a portion of the  filing  checked  above,
identify the item(s) to which the notification relates_________________________

                                     PART I
                             REGISTRANT INFORMATION

Full name of registrant: Paradigm Medical Industries, Inc.

Former name if applicable: ____________________________________________________

Address of principal executive office (Street and number):

                     2355 South 1070 West
                     Salt Lake City, Utah 84119

                                     PART II
                             RULE 12b-25(b) AND (c)

     If the subject  report could not be filed  without  unreasonable  effort or
expense  and the  registrant  seeks  relief  pursuant  to Rule  132b-25(b),  the
following should be completed. (Check box if appropriate).

         (a)      The reasons described in reasonable detail in Part III of this
                  form could not be eliminated  without  unreasonable  effort or

  |X|    (b)      The subject  annual  report,  semi-annual  report,  transition
                  report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion
                  thereof, will be filed on or before the fifteenth calendar day
                  following the  prescribed  due date; or the subject  quarterly
                  report of transition  report on Form 10-Q, or portion  thereof
                  will be filed on or before the fifth  calendar  day  following
                  the prescribed due date; and

         (c)      The  accountant's  statement or other exhibit required by Rule
                  12(b)-25(c) has been attached if applicable.

                                    PART III

         State below in  reasonable  detail the  reasons  why Forms 10-K,  11-K,
10-Q,  N-SAR or the  transition  report or portion  thereof,  could not be filed
within the prescribed time period. (Attach extra sheets if needed.)

         The Form 10-QSB cannot be completed  within the prescribed  time period
due  to  some  complexities  involved  in  completing  the  required  financial
statements and related disclosures pertaining to the sale of convertible notes.

                                     PART IV
                                OTHER INFORMATION

(1)      Name and  telephone  number  of  person  to  contact  in regard to this

           Randall A. Mackey          (801)               575-5000
           -----------------       -----------       ------------------
               (name)              (area code)       (telephone number)

(2)      Have all other periodic  reports  required under Section 13 or 15(d) of
the Securities  Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the  preceding  12 months (or for such  shorter)  period that the
registrant  was  required to file such  report(s)  been filed?  If answer is no,
identify report(s).

         |X| Yes    |_| No

(3)      Is it anticipated that any significant  change in results of operations
from the corresponding  period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?

If so, attach an explanation of the  anticipated  change,  both  narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

         |_| Yes    |X| No

                        Paradigm Medical Industries, Inc.
                  (Name of Registrant as Specified in Charter)

Has  caused  this  notification  to be signed on its  behalf by the  undersigned
hereunto duly authorized.

Date:   August 15, 2007                    By: /s/ Raymond P.L. Cannefax
                                           Raymond P.L. Cannefax
                                           President and Chief Executive Officer